To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Sickle Cell Diseases: Research
Thursday 28th March 2024

Asked by: Andrew Rosindell (Conservative - Romford)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she has taken to support (a) research into and (b) treatment of sickle cell disease in (i) England and (ii) Romford constituency.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

We’re working hard to support research, and provide the best possible care to those living with sickle cell disease (SCD) across the country. The Department funds health and care research through the National Institute for Health and Care Research (NIHR). Over the past five financial years, the NIHR has invested more than £8 million in funding and support for SCD research.

NHS Blood and Transplant (NHSBT) is the largest provider of apheresis services, a blood transfusion used to treat SCD. NHSBT will be delivering projects over the next 12 months that will increase both nursing capacity and the physical space in which apheresis occurs. We are also working to increase Ro subtype blood donation numbers, the blood type used to treat SCD, identify opportunities to improve clinical pathways, and deliver world-leading treatments, such as the new blood matching genetic test announced by NHS England earlier this year, which will reduce the risk of side effects and offer more personalised care.

NHS England’s Chief Executive Officer has committed to improving the treatment and outcomes of patients with SCD, and has commissioned a Sickle Cell Pathway Quality Improvement work package. A quality improvement review of existing processes has led to a range of improvements including awareness, education, and training of both patients and professionals.

The National Healthcare Inequalities Improvement Programme (HiQiP) has recently introduced a number of initiatives as part of the wider aim of tackling inequalities for people living with SCD. This includes: piloting of urgent and emergency department bypass units in London and Manchester, which will ensure people with SCD with an uncomplicated vaso-occlusive crisis are assessed and given pain relief in a timely manner; the provision of a credit card sized Sickle Cell Alert Card to all people with SCD, to alert medical and clinical staff that the carrier is a registered SCD patient and that they should be managed as a medical emergency; a London wide commissioning for the design and upload of a patient care record onto an interoperable digital platform which, when fully operational, will give clinicians and medical personnel in different regions access to a patient’s personalised care and analgesia record, removing ambiguity on effective treatment; and several products to support the above, including a communications campaign to raise awareness of existing NHS England arrangements to support people with SCD to save money on the costs of regular prescriptions, as well as the Can you tell it's Sickle Cell campaign and an e-learning module, both from NHS England. Further information on the Can you tell it's Sickle Cell campaign and the e-learning module is available respectively, at the following links:

https://www.england.nhs.uk/2022/06/nhs-launches-lifesaving-sickle-cell-campaign/

https://www.e-lfh.org.uk/programmes/health-inequalities/


Written Question
Heart Diseases: Research
Thursday 28th March 2024

Asked by: Andrew Rosindell (Conservative - Romford)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she has taken to support (a) research into and (b) treatment of heart disease in (i) England and (ii) Romford constituency.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Department supports research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health, including those relating to heart disease. Over the past five financial years, the NIHR has spent over £64 million on heart-disease related research projects. In addition, the NIHR infrastructure provides clinical expertise, specialist facilities, workforce, and support services to support research across a range of clinical areas, including heart disease.

The Be Part of Research campaign makes it easier for people to find out about, and take part in, health and care research. Currently, there are seven high quality studies related to heart and circulation, which are being supported by the NIHR and are within five miles of Romford.

The NHS Long Term Plan sets out that by 2028 the proportion of patients accessing cardiac rehabilitation will be amongst the best in Europe, with up to 85% of those eligible accessing care. This will prevent up to 23,000 premature deaths and 50,000 acute admissions over 10 years. The NHS Health Check programme is a core component of England's cardiovascular diseases prevention pathway. Over 15 million people are eligible for an NHS Health Check every five years, and it delivers 1.3 million checks a year, preventing an estimated 500 heart attacks and strokes.


Written Question
Obesity: Health Services
Thursday 28th March 2024

Asked by: Mary Glindon (Labour - North Tyneside)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what progress NHS England has made on integrating Wegovy to existing weight management structures within primary care settings.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The National Institute for Health and Care Excellence’s guidance on semaglutide, the active ingredient in wegovy, for managing overweight and obesity was published in March 2023, and updated in September 2023. It recommends semaglutide as a treatment option for patients that meet specified eligibility criteria, and recommends that the treatment is provided within specialist weight management services. These services are typically provided in secondary rather than primary care settings. The Government is committed to the safe introduction of new weight loss drugs into the National Health Service, and is exploring ways to increase access to more people, who meet the relevant eligibility criteria.


Written Question
Bereavement Counselling: Departmental Coordination
Thursday 28th March 2024

Asked by: Peter Gibson (Conservative - Darlington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent progress the cross-government bereavement working group has made on ensuring support is available to bereaved people.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The cross-Government bereavement group was established in preparation for publication of the UK Commission on Bereavement’s (UKCB), Bereavement is Everyone’s Business report, from October 2022. The group includes representatives from over 10 Government departments.

The cross-Government bereavement group enables Government departments to share the best practice about bereavement support in the sectors for which they are responsible. The UKCB Steering Group has presented to the cross-Government working group on several occasions, and last attended a meeting of the group in September 2023.


Written Question
Rare Diseases: Health Services
Thursday 28th March 2024

Asked by: Lord Hay of Ballyore (Democratic Unionist Party - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure equitable access to specialised care and support for patients with rare diseases across England.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

In January 2021, the Government published the UK Rare Diseases Framework, providing a national vision for how to improve the lives of those living with rare diseases. The framework lists four priorities, collaboratively developed with the rare disease community, which are: helping patients get a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatment, and drugs. The principles of the UK Rare Diseases Framework commit the four nations to ensuring that any impacts on health inequalities are considered when developing action plans.

Each year since 2021 we have published an England Rare Diseases Action Plan, with health equity highlighted as a focus area. On 29 February 2024 we published the third England Rare Diseases Action Plan, which is working to address these priorities. Several actions have been committed to in this year and previous year’s action plans, that relate to equitable access to specialised care and support for patients with rare diseases.


Written Question
Haemochromatosis: Research
Thursday 28th March 2024

Asked by: Lord Hay of Ballyore (Democratic Unionist Party - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to support research and development of treatments for patients with haemochromatosis.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Research is currently directly funding one ongoing study on haemochromatosis, and over the last five years, has funded infrastructure to support seven others.


Written Question
NHS: Databases
Thursday 28th March 2024

Asked by: Gregory Campbell (Democratic Unionist Party - East Londonderry)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate he has made of when data will be placed into the federated data platform for NHS trusts and integrated care systems.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Federated Data Platform will allow the National Health Service to make better use of data to improve outcomes for patients, including reducing waits and discharging people quicker from hospital.

45 organisations who participated in the NHS England pilot, broken down into 42 trusts, two integrated care boards, and the City Healthcare Partnership Community Interest Company, have begun to transition into the Federated Data Platform, in a sequence of waves scheduled between March and May 2024. NHS England aims for all trusts and integrated care boards who wish to use the platform to do so within the next three years.


Written Question
Department of Health and Social Care: Staff
Thursday 28th March 2024

Asked by: Neil O'Brien (Conservative - Harborough)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what staff networks there are in her Department.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The following staff-led support networks currently operate in the Department:

- EnABLE, a disability and long-term conditions network;

- Autism Network;

- Attention Deficit Hyperactivity Disorder Network;

- Dyslexia and Dyspraxia Network;

- Race Equality Matters Network;

- Prism, an LGBT+ network;

- Women’s Network;

- Parents’ Network;

- Age Diversity Network;

- Carers’ Network;

- Care Leavers’ Network;

- Social Mobility Network;

- Men’s Health Network;

- Christian Network;

- Jewish Network;

- Muslim Network;

- Hinduism and Sikhism Group;

- Humanists Network;

- Diversity and Inclusion Analytical Network;

- Domestic Abuse Support Group;

- Working Through Cancer Network; and

- Mental Health First Aid.

The following networks support and promote professional development and operational delivery:

- International Network;

- Flexible Working Network;

- Green Network;

- Social Workers Network;

- Health Science and Engineering Network;

- IT User Engagement Group;

- Clinicians’ Network;

- Nutritionist Network;

- Perspectives Network;

- History Network;

- Culture and Engagement Champions Network;

- Active Travel Network;

- International Network;

- First Aid Network;

- Administrative Officer and Executive Officer Network;

- Personal Assistant Network;

- Senior Executive Officer and Higher Executive Officer Network;

- G6 and G7 Network; and

- Direct Appointment Scheme Network.


Written Question
Long Covid: Drugs
Thursday 28th March 2024

Asked by: Ellie Reeves (Labour - Lewisham West and Penge)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she plans to review the eligibility criteria for antivirals for those suffering from long covid.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

Decisions on the eligibility criteria for treatment with antivirals are made by the National Institute for Health and Care Excellence (NICE), based on an assessment of their costs and benefits, developed in line with marketing authorisations issued by the Medicines and Healthcare products Regulatory Agency.

The NICE has published guidance that recommends the antivirals Paxlovid, Veklury, and Lagevrio for the treatment of COVID-19, both in the community, and for patients in hospital. This guidance sets out the eligibility criteria and ensures that patients who are at the highest risk of developing severe disease from COVID-19 have access to clinically and cost-effective treatments. Patients with long COVID have not been identified as a distinct group that would be eligible for treatment, and there are currently no licensed antivirals for the treatment of long COVID. The NICE therefore has no current plans to review the eligibility criteria in its guidance. The NICE maintains surveillance of new evidence that may affect its published guidance, and would consult on proposed changes if significant new evidence were to emerge.


Written Question
Ovarian Cancer: Diagnosis
Thursday 28th March 2024

Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce regional variations in early diagnosis of ovarian cancer.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

Reducing inequalities and variation in cancer treatment is a priority for the Government, as is increasing early cancer diagnosis, as both are key contributors to reducing cancer health inequalities. The National Health Service is improving cancer pathways to get people diagnosed faster once referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 113 NSS pathways are currently operational, with more in development.